[go: up one dir, main page]

BR112022026550A2 - Composição de compostos que modulam o metabolismo celular e métodos de uso - Google Patents

Composição de compostos que modulam o metabolismo celular e métodos de uso

Info

Publication number
BR112022026550A2
BR112022026550A2 BR112022026550A BR112022026550A BR112022026550A2 BR 112022026550 A2 BR112022026550 A2 BR 112022026550A2 BR 112022026550 A BR112022026550 A BR 112022026550A BR 112022026550 A BR112022026550 A BR 112022026550A BR 112022026550 A2 BR112022026550 A2 BR 112022026550A2
Authority
BR
Brazil
Prior art keywords
compounds
composition
methods
cellular metabolism
modulate cellular
Prior art date
Application number
BR112022026550A
Other languages
English (en)
Inventor
KOYUNCU Emre
Hahn Kim
Original Assignee
Crescenta Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescenta Biosciences filed Critical Crescenta Biosciences
Publication of BR112022026550A2 publication Critical patent/BR112022026550A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSIÇÃO DE COMPOSTOS QUE MODULAM O METABOLISMO CELULAR E MÉTODOS DE USO. Uma nova classe de compostos de acordo com a Fórmula I, II ou III, em que W1 ? W4, Z1-Z4, Z1 ? Z5, X, Y, n e R1 ? R8 são conforme definidos nas reivindicações e descrição das modalidades, que se ligam à proteína de ligação a ácidos graxos FABP4 e modulam o metabolismo dos adipócitos para impulsionar a utilização melhorada de glicose, bem como composições farmacêuticas compreendendo a classe de compostos, em combinação com um diluente ou transportador farmaceuticamente aceitável e, opcionalmente, ainda em combinação com um agente terapeuticamente ativo, e o uso destes compostos em medicina e para a preparação de um medicamento no tratamento de distúrbios que atuam na FABP4. Nos exemplos, o anel Z contém Z1-Z4. Em outros exemplos, o anel Z contém Z1-Z5.
BR112022026550A 2020-06-27 2021-06-28 Composição de compostos que modulam o metabolismo celular e métodos de uso BR112022026550A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045079P 2020-06-27 2020-06-27
PCT/US2021/039470 WO2021263246A1 (en) 2020-06-27 2021-06-28 Novel cell metabolism modulating compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112022026550A2 true BR112022026550A2 (pt) 2023-01-17

Family

ID=79166603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026550A BR112022026550A2 (pt) 2020-06-27 2021-06-28 Composição de compostos que modulam o metabolismo celular e métodos de uso

Country Status (11)

Country Link
US (2) US12084419B2 (pt)
EP (1) EP4171736A4 (pt)
JP (1) JP2023532888A (pt)
KR (1) KR20230031322A (pt)
CN (1) CN115803085A (pt)
AU (1) AU2021297465A1 (pt)
BR (1) BR112022026550A2 (pt)
CA (1) CA3184282A1 (pt)
IL (1) IL299002A (pt)
MX (1) MX2023000036A (pt)
WO (1) WO2021263246A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022026550A2 (pt) 2020-06-27 2023-01-17 Crescenta Biosciences Composição de compostos que modulam o metabolismo celular e métodos de uso
WO2022010951A1 (en) * 2020-07-06 2022-01-13 Crescenta Biosciences Antiviral use of fabp4 modulating compounds
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN114456052B (zh) * 2022-01-25 2023-08-25 哈尔滨工业大学（深圳） 一种不饱和羰基或不饱和亚胺化合物的不对称1,4-加成方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3555034A (en) 1968-06-18 1971-01-12 American Home Prod Certain 5,6,7,8-tetrahydro-1,6-naphthyridin-2-ol esters
US3668207A (en) 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
DE2431292A1 (de) 1974-06-27 1976-01-15 Schering Ag Neue carbazol-derivate
CA1326030C (en) * 1987-07-21 1994-01-11 John W. Gillard Cyclohept[b]indolealkanoic acids
EP0307077A1 (en) * 1987-07-21 1989-03-15 Merck Frosst Canada Inc. Tetrahydrocarbazoles for the improvement of cyclosporin therapy
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
AU6130694A (en) 1991-03-05 1994-08-15 Miris Medical Corporation An automatic aerosol medication delivery system and methods
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
US6540154B1 (en) 1991-04-24 2003-04-01 Aerogen, Inc. Systems and methods for controlling fluid feed to an aerosol generator
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
FR2682107B1 (fr) 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5819726A (en) 1993-01-29 1998-10-13 Aradigm Corporation Method for the delivery of aerosolized drugs to the lung for the treatment of respiratory disease
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
PL187750B1 (pl) 1994-09-21 2004-09-30 Nektar Therapeutics Sposób i urządzenie do wytwarzania aerozolu ze sproszkowanego leku
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6427682B1 (en) 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
JP2002524517A (ja) 1998-09-17 2002-08-06 ブリストル−マイヤーズ スクイブ カンパニー ａＰ２阻害剤およびその組成物を用いる糖尿病の治療方法
MXPA01003483A (es) 1998-10-05 2002-09-18 Penn State Res Found Composiciones y metodos para mejorar la internalizacion celular mediada por el receptor.
EP1151092B1 (en) 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
CA2396596A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6543443B1 (en) 2000-07-12 2003-04-08 Aerogen, Inc. Methods and devices for nebulizing fluids
EP1328515B1 (en) 2000-10-16 2008-08-06 F. Hoffmann-La Roche AG Indoline derivatives and their use as 5-ht2 receptor ligands
HUP0500543A2 (hu) 2000-11-20 2005-09-28 Bristol-Myers Squibb Company Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
EP1423366A1 (en) * 2001-08-09 2004-06-02 Eli Lilly And Company Cyclopenta b ! indole derivatives as spla2 inhibitors
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
DE602004008762T2 (de) 2003-04-30 2008-06-12 The Institutes for Pharmaceutical Discovery, LLC, Branford Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
SI2037967T1 (sl) * 2006-06-16 2017-04-26 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije
WO2008062907A1 (en) 2006-11-22 2008-05-29 Sumitomo Chemical Company, Limited Substance capable of inhibiting cytokinin signaling
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
US7722789B2 (en) 2007-11-30 2010-05-25 3M Innovative Properties Company Defoaming method, defoaming device and manufacturing method of transfer mold
US8815875B2 (en) 2008-11-12 2014-08-26 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
HRP20150807T1 (hr) 2009-03-05 2015-09-11 President And Fellows Of Harvard College PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U
US8546382B2 (en) * 2009-04-15 2013-10-01 Children's Medical Center Corporation Methods for enhancing hematopoietic progenitor cell engraftment
WO2010151799A2 (en) 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
US8470879B2 (en) 2009-11-02 2013-06-25 Life Technologies Corporation Fatty acid inhibitors
US8889739B2 (en) 2010-07-09 2014-11-18 President And Fellows Of Harvard College Use of trans-palmitoleate in identifying and treating metabolic disease
US20130116231A1 (en) 2010-07-12 2013-05-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
US8889683B2 (en) 2010-09-27 2014-11-18 Merck Sharp & Dohme Corp. Substituted quinoxalines as inhibitors of fatty acid binding protein
CA2832818A1 (en) 2011-04-06 2012-10-11 The Trustees Of Princeton University Anti-viral combination therapy
KR20130047623A (ko) * 2011-10-28 2013-05-08 주식회사종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 하이드록사메이트 유도체 및 이를 포함하는 약제학적 조성물
KR20140088194A (ko) 2011-11-04 2014-07-09 에프. 호프만-라 로슈 아게 아릴-퀴놀린 유도체
WO2013177241A1 (en) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
WO2013189841A1 (en) 2012-06-19 2013-12-27 F. Hoffmann-La Roche Ag New bicyclic thiophenylamide compounds
EP2874987B1 (en) 2012-07-20 2020-03-25 The Research Foundation Of State University Of New York alpha-AND gamma-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO2014029723A1 (en) 2012-08-24 2014-02-27 F. Hoffmann-La Roche Ag New bicyclicpyridine derivatives
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
CN104619705B (zh) 2012-09-12 2018-01-02 霍夫曼-拉罗奇有限公司 作为脂肪酸结合蛋白(fabp)4和/或5的抑制剂的非成环噻吩基酰胺
US20150330992A1 (en) 2012-12-12 2015-11-19 The Regents Of The University Of California Rapid discovery and screening of enzyme activity using mass spectrometry
WO2014146994A1 (en) 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014177593A1 (en) 2013-04-29 2014-11-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Amorfrutin analogs as ppargamma-modulators
AR096614A1 (es) 2013-06-13 2016-01-20 Monsanto Technology Llc Moduladores de la acetil-coa carboxilasa
WO2014201327A1 (en) 2013-06-13 2014-12-18 Monsanto Technology Llc Acetyl-coa carboxylase modulators
US9855049B2 (en) * 2013-12-11 2018-01-02 Miracor Medical Systems Gmbh System and method for treating heart tissue
ES2705773T3 (es) 2014-09-09 2019-03-26 Bristol Myers Squibb Co Moduladores de GPR120 de ácido ciclopropanocarboxílico
EP3209794A1 (en) 2014-10-22 2017-08-30 Katholieke Universiteit Leuven KU Leuven Research & Development Modulating adipose tissue and adipogenesis
US9968616B2 (en) * 2014-10-25 2018-05-15 The Chinese University Of Hong Kong Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
CA2994717A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Heterocyclic compounds useful as modulators of tnf alpha
US11130736B2 (en) 2015-08-21 2021-09-28 University Of Kansas Human TLR8-selective agonists
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
EP3246028A1 (en) 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline compounds for increasing insuline release
WO2018078624A1 (en) 2016-10-25 2018-05-03 Ticure Ltd. Fabp4 as a therapeutic target in skin diseases
US10650911B2 (en) 2017-06-13 2020-05-12 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
US11434195B2 (en) 2017-07-20 2022-09-06 University Of Florida Research Foundation, Inc. Compositions and methods for treatment of central nervous system tumors
BR112022026550A2 (pt) 2020-06-27 2023-01-17 Crescenta Biosciences Composição de compostos que modulam o metabolismo celular e métodos de uso

Also Published As

Publication number Publication date
US20220002243A1 (en) 2022-01-06
EP4171736A1 (en) 2023-05-03
JP2023532888A (ja) 2023-08-01
MX2023000036A (es) 2023-02-01
CA3184282A1 (en) 2021-12-30
US12084419B2 (en) 2024-09-10
US20230331673A1 (en) 2023-10-19
EP4171736A4 (en) 2024-07-03
CN115803085A (zh) 2023-03-14
IL299002A (en) 2023-02-01
KR20230031322A (ko) 2023-03-07
WO2021263246A1 (en) 2021-12-30
AU2021297465A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
BR112022026550A2 (pt) Composição de compostos que modulam o metabolismo celular e métodos de uso
Chen et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update)
BR112022014245A2 (pt) Compostos de modulação do metabolismo celular inovadores e usos dos mesmos
BR112022015002A2 (pt) Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
Ornetti et al. Does platelet-rich plasma have a role in the treatment of osteoarthritis?
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
BR112022008744A2 (pt) Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
Shree et al. Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
BR112013003186A2 (pt) composições e métodos para tratamento de doença cardiovascular
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
BR112014011981A2 (pt) formulações farmacêuticas
EP4058022A1 (en) (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
IL292770A (en) Formulations and doses of pegylated uricase
BR112022019510A2 (pt) Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher
Titeux et al. Emerging drugs for the treatment of epidermolysis bullosa
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BR112023019967A2 (pt) Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
BR112023025331A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
WO2023150493A3 (en) Cell therapy for diabetes